Advertisement

Advertisement

Pancreatic Cancer

Adjuvant Chemotherapy After Pancreatic Cancer Resection and Neoadjuvant FOLFIRINOX: Improvement in Overall Survival?

In a retrospective cohort study reported in JAMA Oncology, van Roessel et al found that adjuvant chemotherapy after pancreatic cancer resection and neoadjuvant FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and oxaliplatin) was associated with an improvement in overall survival. The benefit was...

Pancreatic Cancer

Researchers Report on Comprehensive Analysis of Adenosquamous Carcinoma of the Pancreas

In a comprehensive analysis of adenosquamous cancer of the pancreas in preclinical models, researchers identified potential therapeutic targets for this aggressive form of pancreatic cancer. They also identified already-available agents—designed to treat other types of cancer—that may be useful in...

Pancreatic Cancer
Neuroendocrine Tumors

Research Provides Genetic, Immune-Related Information on Pancreatic Neuroendocrine Tumors

Scientists have used artificial intelligence in an extensive analysis of the immune and genetic landscapes of pancreatic neuroendocrine tumors. Their findings were published by Young et al in the journal Gut. Pancreatic neuroendocrine cancer starts in cells that produce hormones such as insulin....

Pancreatic Cancer

Sortilin May Be a Potential Therapeutic Target in Pancreatic Cancer

In a study published by Gao et al in The American Journal of Pathology, scientists reported the discovery of an increased level of the neuroprotein sortilin in pancreatic cancer cells. The investigators speculated that this finding may lead to the development of more effective treatment for...

Pancreatic Cancer

ASCO Updates Metastatic Pancreatic Cancer Guideline

ASCO has released an update to its Metastatic Pancreatic Cancer Guideline that includes recommendations for second-line treatment, including early biomarker testing for actionable genomic alterations.1 Last updated in 2018, this new version was triggered by novel evidence related to targeted...

Kidney Cancer
Lung Cancer
Myelodysplastic Syndromes
Solid Tumors
Skin Cancer
Lymphoma
Pancreatic Cancer
Breast Cancer
Immunotherapy

FDA Pipeline: Designations in Kidney and Lung Cancers, Myelodysplastic Syndromes, and More

Over the past few weeks, the U.S. Food and Drug Administration (FDA) has issued designations and accepted applications for novel agents, as well as approved companion diagnostics. We summarize these regulatory movements below. Breakthrough Therapy Designation for MK-6482 in von Hippel-Lindau...

Pancreatic Cancer

Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer

In the phase III HALO 109-301 trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the addition of pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel plus gemcitabine (AG) did not improve overall survival or progression-free survival in patients...

Pancreatic Cancer

First-Line Liposomal Irinotecan–Containing Regimen Studied in Advanced Pancreatic Cancer

In patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma, treatment with liposomal irinotecan plus fluorouracil (5-FU), leucovorin, and oxaliplatin (NALIRIFOX) resulted in a median progression-free survival of 9.2 months and a median overall survival of 12.6 months, ...

Pancreatic Cancer

SWOG S1505 Trial Evaluates Neoadjuvant Regimens in Pancreatic Cancer

The much-anticipated SWOG S1505 trial has failed to show that one preoperative regimen is better than another in resectable pancreatic cancer.1 “Perioperative modified FOLFIRINOX and gemcitabine/nab-paclitaxel appear to have similar efficacy, with acceptable safety and resectability rates,”...

Pancreatic Cancer

First-Line FOLFIRINOX vs Gemcitabine/Nab-paclitaxel for Localized Pancreatic Cancer

In a single-institution retrospective study reported in JAMA Surgery, Perri et al found that first-line FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) was associated with a higher response rate and subsequent pancreatectomy vs gemcitabine plus nab-paclitaxel in patients with...

Prostate Cancer
Pancreatic Cancer
Lymphoma

FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...

Pancreatic Cancer

Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Pancreatic Cancer Across Age Groups: Additional Analysis of the POLO Trial

According to an additional analysis from the POLO trial, safety of maintenance olaparib in patients with a germline BRCA1 and/or BRCA2 mutation and metastatic pancreatic cancer is consistent, irrespective of age. Patients aged ≥ 65 years derived long-term progression-free survival benefit and...

Colorectal Cancer
Pancreatic Cancer
Lymphoma
Hematologic Malignancies
Kidney Cancer
Gastroesophageal Cancer
Gastrointestinal Cancer

FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia

Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...

Pancreatic Cancer
Genomics/Genetics

First-Line Platinum-Based Chemotherapy for Patients With Metastatic Pancreatic Cancer and Defects in Homologous Recombination Genes

Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy compared to patients without these mutations, according to results from a study published by Park et al in Clinical Cancer Research....

Pancreatic Cancer

Relationship Between Type 3c Diabetes and Pancreatic Cancer

According to the results of a European case-control study published by Molina-Montes et al in the journal Gut, one of the most recently identified types of diabetes—type 3c, or pancreatogenic diabetes—could also be an early manifestation of pancreatic cancer. Pancreatic cancer has a high mortality...

Pancreatic Cancer
Prostate Cancer

Data From TAPUR Study Cohorts on Olaparib for BRCA-Mutated Advanced Prostate and Pancreatic Cancers

Positive results from two cohorts of the Targeted Agent and Profiling Utilization Registry (TAPUR) study provide real-world evidence to support recent clinical trial data that demonstrate a role for olaparib in the treatment of advanced prostate and pancreatic cancers with BRCA1/2-inactivating...

Leukemia
Pancreatic Cancer
Neuroendocrine Tumors
Lung Cancer
Gynecologic Cancers
Lymphoma

FDA Pipeline: Priority Review in AML, Fast Track Designations for Pancreatic Cancer and Neuroendocrine Tumors

Over the past 2 weeks, the U.S. Food and Drug Administration (FDA) granted Priority Review to a treatment for acute myeloid leukemia (AML); Fast Track designations for agents in pancreatic cancer and pancreatic/nonpancreatic neuroendocrine tumors; approvals for companion diagnostic tests;...

Pancreatic Cancer

Risk-Prediction Model for Pancreatic Cancer

A risk-prediction model that combined genetic and clinical factors with circulating biomarkers may help to identify people at a significantly higher-than-normal risk of developing pancreatic cancer, according to results of a study published by Peter Kraft, PhD, and colleagues in Cancer...

Colorectal Cancer
Gastrointestinal Cancer
Hepatobiliary Cancer
Pancreatic Cancer

Aspirin Use and Risk of Cancers of the Digestive Tract

Aspirin may be associated with a reduction in the risk of developing several cancers of the digestive tract. The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers, published by Bosetti et al in Annals of Oncology, found reductions in the risk of ...

Pancreatic Cancer

Living A Full Life After Pancreatic Cancer

I have been a radiologic technologist for 47 years, so after going to the bathroom one Sunday morning in October 2018 and finding my urine had suddenly turned dark, I knew something was wrong. I wasn’t in any pain and did not have a urinary tract infection, which would explain the discoloration of...

Lung Cancer
Pancreatic Cancer
Immunotherapy

Expert Point of View: Timothy A. Yap, MBBS, PhD, FRCP

Semaphorin 4D (SEMA4D, and its receptor, plexin B1) is broadly expressed in malignant tumors. Aside from other “normal functions” in tumors, SEMA4D influences the infiltration and distribution of leukocytes into the microenvironment, and its inhibition promotes functional immune infiltration....

Lung Cancer
Pancreatic Cancer
Immunotherapy

SEMA4D Inhibition: A Novel Means of Improving Immune Response

A novel class of inhibitors may hold some promise for boosting responses to checkpoint inhibitors and for sensitizing poorly immunogenic tumors, such as pancreatic cancer, to immunotherapy. The drug targets semaphorin 4D (SEMA4D), a glycoprotein expressed on the cell membranes of many tumor types....

Pancreatic Cancer

Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...

Pancreatic Cancer

Cisplatin/Gemcitabine Alone and With Veliparib in BRCA-Mutated Advanced Pancreatic Cancer

In patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, first-line therapy with cisplatin plus gemcitabine yielded high response rates and encouraging survival, according to Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, who presented the findings...

Pancreatic Cancer
Genomics/Genetics

Genetic Counseling and Testing of Patients With Pancreatic Cancer

Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute in Boston, the use of a systemized, automated referral system ...

Pancreatic Cancer

Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer Yields Improved Progression-Free Survival, Preserves Quality of Life

Health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 POLO investigators reported their findings in posters presented at the 2020 Gastrointestinal Cancers Symposium. Other...

Gastroesophageal Cancer
Gastrointestinal Cancer
Colorectal Cancer
Hepatobiliary Cancer
Pancreatic Cancer

Conference Highlights From the 2020 Gastrointestinal Cancers Symposium

This past January, the 2020 Gastrointestinal Cancers Symposium was held in San Francisco. More than 3,600 individuals attended and more than 900 abstracts and posters were presented. Among the highlights presented at the meeting and reported in the pages of The ASCO Post, several studies in...

Pancreatic Cancer

Study Focuses on Role of Microbes in Pancreatic Cancer

Although bacteria are predominant in the gastrointestinal tract, they also reside on and in other parts of the body, including some unexpected places, such as malignant tumors. There are numerous reports of this phenomenon, but most have not identified a functional role for the microbes. In the...

Pancreatic Cancer

Survival in Patients With Pancreatic Cancer Receiving Molecularly Matched Therapies

In a retrospective study reported in The Lancet Oncology, Michael J. Pishvaian, MD, and colleagues found that overall survival was better in patients with pancreatic cancer with actionable molecular alterations who received matched therapies compared with those who received only unmatched therapies ...

Pancreatic Cancer

Preoperative Chemoradiotherapy vs Immediate Surgery for Pancreatic Cancer

In the Dutch phase III PREOPANC trial reported in the Journal of Clinical Oncology, Versteijne et al found that preoperative chemoradiotherapy did not improve overall survival vs immediate surgery in patients with resectable and borderline resectable pancreatic cancer. Benefits of preoperative...

Genomics/Genetics
Pancreatic Cancer
Issues in Oncology

Geographic and Racial Variability in Germline BRCA Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer

In a study reported in the Journal of Clinical Oncology, Talia Golan, MD, and colleagues identified geographic and ethnic heterogeneity of germline BRCA1/2 mutation prevalence among patients screened for entry into the phase III POLO trial, which examined the efficacy of olaparib maintenance...

Pancreatic Cancer

New POLO Data Further Support Maintenance Olaparib in BRCA1/2-Positive Pancreatic Cancer

In posters presented at the 2020 Gastrointestinal Cancers Symposium, POLO investigators reported that health-related quality of life was preserved during maintenance olaparib in patients with BRCA 1/2-positive pancreatic cancer, as evidenced by a low symptom burden over time.1 Other studies...

Pancreatic Cancer
Genomics/Genetics

Automated Referral Process for Genetic Counseling and Testing of Patients With Pancreatic Cancer

Routine genetic counseling and multigene testing of patients with pancreatic cancer result in the detection of mutations that are actionable, not only for patients, but also for at-risk family members. At the Dana-Farber Cancer Institute, the use of a systemized, automated referral system that does ...

Pancreatic Cancer

Expert Point of View: Andrea Wang-Gillam, MD, PhD

Andrea Wang-Gillam, MD, PhD, Clinical Director of the GI Oncology Program and Director of Developmental Therapeutics at Washington University in St. Louis, was the invited discussant of SEQUOIA and HALO 109-301. She tried to make sense of the two negative studies of pegylated agents in advanced...

Pancreatic Cancer

Two Novel Pegylated Agents Fail in Metastatic Pancreatic Cancer

Two novel treatments once thought to hold promise in the treatment of metastatic pancreatic cancer have not proved to be effective in phase III trials, investigators reported at the 2020 Gastrointestinal Cancers Symposium. When combined with standard chemotherapy, a pegylated form of human...

pancreatic cancer
immunotherapy

Luis I. Ruffolo, MD, on Pancreatic Cancer: Augmenting Immunotherapy With Antibody Blockade of Semaphorin 4D

Luis I. Ruffolo, MD, of the University of Rochester, discusses preclinical studies showing that semaphorin 4D blockade may sensitize pancreatic tumors to chemoimmunotherapy combinations (Abstract 26).

pancreatic cancer

Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA

Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97 patients with pancreatic ductal adenocarcinoma with circulating tumor DNA. Mutations were most frequently detected in patients with locally advanced and metastatic disease (Abstract 753).

Pancreatic Cancer

Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO

Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, who is also a gastrointestinal oncologist, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free ...

Pancreatic Cancer

‘Unprecedented’ Responses to Cisplatin/Gemcitabine in BRCA-Mutated Advanced Pancreatic Cancer

As first-line treatment of patients with pancreatic ductal adenocarcinoma and a germline BRCA/PALB2 mutation, cisplatin plus gemcitabine yielded high response rates and encouraging survival, establishing this doublet as a standard approach in this subset of patients, according to Eileen M....

pancreatic cancer

Eileen M. O’Reilly, MD, on Pancreatic Adenocarcinoma: Gemcitabine, Cisplatin, and Veliparib

Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceeded a prespecified response rate for patients with pancreatic adenocarcinoma and a germline BRCA/PALB2 mutation (Abstract 639).

Pancreatic Cancer
Cost of Care

2020 GI Cancers Symposium: Cost of Pancreatic Cancer Care Over Time

In a study presented by Picozzi et al at the 2020 Gastrointestinal Cancers Symposium, researchers found that even as drug costs increased over the past decade, total inflation-adjusted pancreatic cancer care expenses declined, as did costs related to quality of life (Abstract 773). Health...

Pancreatic Cancer

Olaparib as Maintenance Therapy for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma

On December 27, 2019, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma, as detected by a U.S. Food and Drug Administration...

Pancreatic Cancer
Genomics/Genetics

Genomic Aberrations and Pancreatic Cancer Subtypes

Researchers have discovered detailed new genetic information about the subtypes of pancreatic cancer. A better understanding of the disease groups may lead to new treatment options and improved clinical outcomes for this lethal disease, Chan-Seng-Yue et al reported in Nature Genetics. The study...

Pancreatic Cancer

FDA Approves Olaparib for Patients With Germline BRCA-Mutated Metastatic Pancreatic Cancer

On December 27, 2019, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma as detected by an FDA-approved test whose disease has not ...

Colorectal Cancer
Head and Neck Cancer
Pancreatic Cancer

Early Research Shows Potential New Targets in Treating Glioblastoma, Colorectal Cancer, and Pancreatic Ductal Adenocarcinoma

Glioblastoma multiforme, colorectal cancer, and pancreatic ductal adenocarcinoma represent some of the most difficult-to-treat cancers and collectively cause more than 114,000 deaths each year in the United States. A trio of recently published basic research studies in these cancers have found...

Immunotherapy
Pancreatic Cancer

ESMO Immuno-Oncology 2019: CXCR4 Inhibitor in Combination With Pembrolizumab/Chemotherapy for Metastatic Pancreatic Cancer

When the CXCR4 inhibitor BL-8040 was combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab plus chemotherapy in the second-line setting, the regimen showed promising antitumor activity in patients with metastatic pancreatic ductal adenocarcinoma. These findings were...

Prostate Cancer
Breast Cancer
Bladder Cancer
Pancreatic Cancer
Kidney Cancer
Thyroid Cancer
Gynecologic Cancers
Immunotherapy

ESMO Congress 2019: Quick Takes From Key Clinical Trials

The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...

Pancreatic Cancer

Management of Locally Advanced Pancreatic Cancer: A Call for Action

Advances in systemic therapy and supportive care, as well as ongoing improvements in surgical techniques, have led to improved survival for many patients with pancreatic ductal adenocarcinoma. We have observed increased survival with FOLFIRINOX (leucovorin, fluorouracil, irinotecan,...

Pancreatic Cancer
Global Cancer Care

Global Burden of Pancreatic Cancer From 1990–2017

The incidence and mortality rates of pancreatic cancer have increased in 195 countries and territories over a 27-year period, according to a systematic analysis performed within the Global Burden of Disease Study 2017 and published in The Lancet Gastroenterology & Hepatology. The study is the...

Pancreatic Cancer

Nab-paclitaxel/Gemcitabine/Cisplatin for Previously Untreated, Advanced Pancreatic Cancer

In a phase Ib/II pilot study reported in JAMA Oncology, Jameson et al found that treatment with nab-paclitaxel, gemcitabine, and cisplatin was active in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Study Details In the study, 25 patients were enrolled between...

Advertisement

Advertisement

Advertisement